News Release

Plozasiran (ARO-APOC3) for severe hypertriglyceridemia

JAMA Cardiology

Peer-Reviewed Publication

JAMA Network

About The Study: This randomized clinical trial demonstrates the potential clinical utility of plozasiran, an investigational APOC3-targeted small interfering–RNA drug, to reduce triglyceride level in patients with severe hypertriglyceridemia. Additional studies will be required to determine whether plozasiran favorably modulates the risk of severe hypertriglyceridemia-associated complications. 

Authors: Daniel Gaudet, M.D., Ph.D., of the Université de Montréal, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the American College of Cardiology’s Annual Scientific Session. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.